An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic.

@article{Fernndez2007AnAC,
  title={An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic.},
  author={Ariel Fern{\'a}ndez and Angela Sanguino and Zhenghong Peng and Eylem Ozturk and Jian-ping Chen and Alejandro D Crespo and Sarah Wulf and Aleksander Shavrin and Chaoping Qin and Jianpeng Ma and Jonathan A Trent and Yvonne H Lin and H S Han and Lingegowda Selanere Mangala and James A Bankson and Juri Gelovani and Allen M. Samarel and William G. B. Bornmann and Anil Sood and Gabriel L{\'o}pez-Berestein},
  journal={The Journal of clinical investigation},
  year={2007},
  volume={117 12},
  pages={4044-54}
}
Targeting kinases is central to drug-based cancer therapy but remains challenging because the drugs often lack specificity, which may cause toxic side effects. Modulating side effects is difficult because kinases are evolutionarily and hence structurally related. The lack of specificity of the anticancer drug imatinib enables it to be used to treat chronic… CONTINUE READING